International Journal of Clinical Science and Medical Research

Introduction : Glanzmann's thrombasthenia (GT) is a rare bleeding disorder caused by quantitative or qualitative abnormalities of the platelet membrane glycoprotein IIb/IIIa, which is involved in platelet aggregation. This study aimed to describe the clinical and biological profiles of patients with GT and to evaluate the diagnostic performance of platelet aggregometry test in confirming this rare disorder.

Material and methods : This study involved 8 patients presenting with clinical symptoms of mucocutaneous bleeding and suspected inherited platelet disorder. Platelet aggregation test was performed on platelet-rich plasma (PRP) using a panel of physiological agonists, including adenosine diphosphate (ADP), collagen, epinephrine, and arachidonic acid. Ristocetin-induced platelet aggregation was assessed to differentiate GT from other macrothrombocytopenias.

Results : Hemorrhagic symptoms included mucocutaneous bleeding (epistaxis, ecchymosis, gingival hemorrhage). Both the platelet count and routine hemostasis tests showed normal physiological values. Platelet aggregometry test revealed a pathognomonic profile in all eight cases : a near-total absence of aggregation in response to physiological agonists, contrasted with a preserved or subnormal response to ristocetin.

Conclusion : Our study confirm that platelet aggregometry test remains the definitive gold standard for the biological diagnosis of GT. Despite its technical complexity necessitating centralization in specialized reference laboratories, it provides a reliable and essential functional assessment for the management and classification of this rare hemorrhagic disorder.

Thrombasthenia, Platelet-Rich plasma, Platelet Aggregation Test, Blood Platelet Disorders, Ristocetin

1. Iqbal I, Farhan S, Ahmed N. Glanzmann Thrombasthenia: A Clinicopathological Profile. J Coll Physicians Surg Pak. 2016 Aug;26(8):647-50. PMID: 27539755.
2. Palma-Barqueros V, Revilla N, Sánchez A, Zamora Cánovas A, Rodriguez-Alén A, Marín-Quílez A, González-Porras JR, Vicente V, Lozano ML, Bastida JM, Rivera J. Inherited Platelet Disorders: An Updated Overview. Int J Mol Sci. 2021 Apr 26;22(9):4521. doi: 10.3390/ijms22094521. PMID: 33926054; PMCID: PMC8123627.
3. Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders. Haemophilia. 2012 Jul;18 Suppl 4:154-60. doi: 10.1111/j.1365-2516.2012.02856.x. PMID: 22726100.
4. Doherty D, Singleton E, Byrne M, Ryan K, O'Connell NM, O'Donnell JS, Lavin M. Missed at first Glanz: Glanzmann thrombasthenia initially misdiagnosed as Von Willebrand Disease. Transfus Apher Sci. 2019 Feb;58(1):58-60. doi: 10.1016/j.transci.2018.11.008. Epub 2018 Dec 5. PMID: 30551951.
5. Elalamy I. Acquired and Congenital Thrombopathies. EMC Elsevier. 2006; 13-021-A-10.
6. Sheikh AY, Hill CC, Goodnough LT, Leung LL, Fischbein MP. Open aortic valve replacement in a patient with Glanzmann's thrombasthenia: a multidisciplinary strategy to minimize perioperative bleeding. Transfusion. 2014 Feb;54(2):300-5. doi: 10.1111/trf.12275. Epub 2013 May 27. PMID: 23710629.
7. Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost. 2013 Sep;39(6):642-55. doi: 10.1055/s-0033-1353393. Epub 2013 Aug 8. PMID: 23929305; PMCID: PMC4011384.

1. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006 Apr 6 ;1 :10. doi: 10.1186/1750-1172-1-10. PMID : 16722529 ; PMCID : PMC1475837.
2. Mukendi JL, Benkirane S, Masrar A. Thrombasthénie de Glanzmann : à propos de 11 cas [Glanzmann thrombasthenia: about 11 cases]. Pan Afr Med J. 2015 Aug 11 ;21 :268. French. doi: 10.11604/pamj.2015.21.268.6502. PMID : 26587119 ; PMCID : PMC4633832.
3. Zohair Ait Ouzdi, Fatimazahra Marhoume, Khalil Haouach. Glanzmann Thrombasthenia: A Case Report in Moroccan Child. American Journal of Laboratory Medicine. Vol. 3, No. 5, 2018, pp. 44-47. doi: 10.11648/j.ajlm.20180305.12
4. Mukendi JL, Benkirane S, Masrar A. Thrombasthénie de Glanzmann: à propos de 11 cas [Glanzmann thrombasthenia: about 11 cases]. Pan Afr Med J. 2015 Aug 11;21:268. French. doi: 10.11604/pamj.2015.21.268.6502. PMID: 26587119; PMCID: PMC4633832.
5. F et al. Glanzmann's thrombasthenia: report of a pediatric experience. J.I. M. Sfax, No. 32; June 19; 50 – 56
6. Fiore, Mathieu. 2014. "Extension of the mutational spectrum of the ITGA2B-ITGB3 genes and genotype-phenotype correlation in Glanzmann's thrombasthenia." PhD thesis, University of Bordeaux. https://tel.archives-ouvertes.fr/tel-01182690.
7. Palma-Barqueros V, Revilla N, Sánchez A, Zamora Cánovas A, Rodriguez-Alén A, Marín-Quílez A, González-Porras JR, Vicente V, Lozano ML, Bastida JM, Rivera J. Inherited Platelet Disorders: An Updated Overview. Int J Mol Sci. 2021 Apr 26;22(9):4521. doi: 10.3390/ijms22094521. PMID: 33926054; PMCID: PMC8123627.
8. Bellucci S, Caen J. Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev. 2002 Sep;16(3):193-202. doi: 10.1016/s0268-960x(02)00030-9. PMID: 12163005.
9. Nurden P, Nurden A. Pathologies plaquettaires héréditaires. In : Manuel d’hémostase. Paris ; Elsevier, 1995
10. Al-Huniti A, Kahr WH. Inherited Platelet Disorders: Diagnosis and Management. Transfus Med Rev. 2020 Oct;34(4):277-285. doi: 10.1016/j.tmrv.2020.09.006. Epub 2020 Sep 19. PMID: 33082057.
11. Nurden AT, Nurden P. Glanzmann Thrombasthenia 10 Years Later: Progress Made and Future Directions. Semin Thromb Hemost. 2025 Mar;51(2):196-208. doi: 10.1055/s-0044-1782519. Epub 2024 Mar 18. PMID: 38499192.